Janux Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Janux reported Q2 2026 results with $970.9M in cash/equivalents/short-term investments (up $4.3M from Dec 2025), Q2 net loss of $22.0M (improved from $33.9M YoY), and R&D expenses of $31.0M (down from $34.7M YoY). JANX007 Phase 1b enrollment ongoing in mCRPC with darolutamide combination cohort; JANX014 Phase 1 continuing; JANX011 Phase 1 healthy volunteer study progressing; JANX013 initiation expected H2 2026. Collaboration revenue of $10.3M in Q2 2026 (none in Q2 2025).
Why this rating
Cash position strong relative to burn rate (~$89.8M annualized), but routine biotech progress disclosure. No material clinical data, partnerships, or financing changes—standard quarterly update for clinical-stage firm.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.